Edwards Lifesciences

EWleader

Edwards Lifesciences is the global leader in transcatheter heart valve therapies, particularly TAVR, which has transformed treatment for aortic stenosis from open-heart surgery to a catheter-based procedure.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($6.4B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Transcatheter Aortic Valve (60%)

Surgical Structural Heart (15%)

Critical Care (15%)

TMTT (10%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

TAVR (SAPIEN)60%

Transcatheter aortic valve replacement systems for heart valve disease

TMTT10%

Transcatheter mitral and tricuspid valve therapies in development

Surgical Structural Heart15%

Surgical heart valves and repair products

Critical Care15%

Hemodynamic monitoring and smart recovery technologies

Lieferkettenbeziehungen

Wettbewerber

Medtronic

CoreValve TAVR system

Auswirkung: Primary TAVR competitor

Abbott Laboratories

Structural heart portfolio

Auswirkung: Growing competitor in structural heart

Boston Scientific

ACURATE valve

Auswirkung: Emerging TAVR competitor

Makro- und Marktkontext

헬스케어Sektornachrichten

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Nächste Katalysatoren

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Edwards Lifesciences.

Unternehmensinformationen

Hauptsitz

Irvine, California, USA

Gegründet

1958

Mitarbeiter

20,000+

Website

edwards.com

Sektorübersicht — 헬스케어

Sektornachrichten